Detection of Ovarian Cancer Antigen CF511
Author Information
Author(s): K. Ohkawa, K. Takada, T. Hatanol, N. Takizawa, Y. Tsukada, K. Yamada, Y. Terashima, M. Matsuda, K. Machida
Primary Institution: Jikei University School of Medicine
Hypothesis
The study aims to determine the serum levels of CF511 antigen in various populations and assess its usefulness for monitoring ovarian carcinoma.
Conclusion
The CF511 antigen levels are elevated in most patients with advanced ovarian carcinoma and can be useful for monitoring disease progression.
Supporting Evidence
- CF511 antigen was detected in 42.3% of early-stage ovarian carcinoma patients and 96.0% of advanced-stage patients.
- Only 13% of patients with benign gynaecological diseases showed elevated CF511 antigen levels.
- CF511 antigen levels correlated with the clinical course of disease in patients monitored before and after surgery.
Takeaway
Doctors can use a special test to find a protein called CF511 in the blood, which helps them see if someone has ovarian cancer.
Methodology
A competitive enzyme-linked immunosorbent assay (ELISA) was developed to detect CF511 antigen levels in serum samples from patients and healthy individuals.
Limitations
The study may have a low specificity and sensitivity, and the correlation with other tumor markers was not significant.
Participant Demographics
Included patients with ovarian carcinoma, benign gynaecological diseases, and healthy individuals.
Want to read the original?
Access the complete publication on the publisher's website